200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 236395-14-5
236395-14-5 | 5H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-
CAS No: 236395-14-5 Catalog No: AG002NZQ MDL No:MFCD06798333
Product Description
Catalog Number:
AG002NZQ
Chemical Name:
5H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-
CAS Number:
236395-14-5
Molecular Formula:
C17H16N2O3
Molecular Weight:
296.3205
MDL Number:
MFCD06798333
IUPAC Name:
[(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate
InChI:
InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
InChI Key:
QIALRBLEEWJACW-INIZCTEOSA-N
SMILES:
CC(=O)O[C@H]1Cc2ccccc2N(c2c1cccc2)C(=O)N
UNII:
BEA68ZVB2K
Properties
Complexity:
440
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
296.116g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
296.326g/mol
Monoisotopic Mass:
296.116g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
72.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2
Literature
| Title | Journal |
|---|---|
| The Efficacy of Eslicarbazepine Acetate in Models of Trigeminal, Neuropathic, and Visceral Pain: The Involvement of 5-HT1B/1D Serotonergic and CB1/CB2 Cannabinoid Receptors. | Anesthesia and analgesia 20151201 |
| A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. | Therapeutic advances in neurological disorders 20150701 |
| Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. | Expert opinion on drug metabolism & toxicology 20150401 |
| Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. | Pharmacology research & perspectives 20150301 |
| Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. | Epilepsia 20150201 |
| Clinical utility of eslicarbazepine: current evidence. | Drug design, development and therapy 20150101 |
| Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. | BMC neurology 20150101 |
| Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. | Epilepsy research 20140901 |
| The effects of eslicarbazepine on persistent Na⁺ current and the role of the Na⁺ channel β subunits. | Epilepsy research 20140201 |
| Aptiom (eslicarbazepine acetate) as a dual inhibitor of β-secretase and voltage-gated sodium channel: advancement in Alzheimer's disease-epilepsy linkage via an enzoinformatics study. | CNS & neurological disorders drug targets 20140101 |
| Pharmacokinetics and drug interactions of eslicarbazepine acetate. | Epilepsia 20120601 |
| [Eslicarbazepine acetate: a novel therapeutic alternative in the treatment of focal seizures]. | Revista de neurologia 20120501 |
| Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. | Expert opinion on pharmacotherapy 20120401 |
| Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS. | Journal of pharmaceutical and biomedical analysis 20120305 |
| Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. | CNS drugs 20120101 |
| Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. | The Cochrane database of systematic reviews 20111207 |
| Eslicarbazepine acetate for partial-onset seizures. | Expert review of neurotherapeutics 20111201 |
| In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. | Epilepsia 20111001 |
| [New antiepileptic drugs, and therapeutic considerations]. | Ideggyogyaszati szemle 20110930 |
| Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. | Drug metabolism and disposition: the biological fate of chemicals 20110901 |
| Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. | Epilepsy research 20110901 |
| Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110901 |
| [Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate]. | Der Nervenarzt 20110601 |
| A chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: eslicarbazepine acetate, carbamazepine and main metabolites. | Journal of separation science 20110601 |
| Development of liquid chromatographic enantiomer separation methods and validation for the estimation of (R)-enantiomer in eslicarbazepine acetate. | Journal of pharmaceutical and biomedical analysis 20110105 |
| Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. | Epilepsia 20101001 |
| Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites. | Therapeutic drug monitoring 20100801 |
| Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. | Epilepsy & behavior : E&B 20100801 |
| Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. | Current medical research and opinion 20100601 |
| Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. | Analytical and bioanalytical chemistry 20100601 |
| Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. | Epilepsy research 20100501 |
| Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. | Acta neurologica Scandinavica 20100401 |
| Key factors in the discovery and development of new antiepileptic drugs. | Nature reviews. Drug discovery 20100101 |
| Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. | Clinical therapeutics 20100101 |
| Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy. | Drugs of today (Barcelona, Spain : 1998) 20100101 |
| Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. | Acta neurologica Scandinavica 20091101 |
| Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. | Fundamental & clinical pharmacology 20090801 |
| Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. | International journal of clinical pharmacology and therapeutics 20090401 |
| Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. | Epilepsia 20090301 |
| Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. | Expert opinion on investigational drugs 20090201 |
| Eslicarbazepine acetate. | CNS drugs 20090101 |
| Disposition of eslicarbazepine acetate in the mouse after oral administration. | Fundamental & clinical pharmacology 20081001 |
| Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. | Journal of clinical pharmacology 20080801 |
| Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. | European journal of clinical pharmacology 20080301 |
| Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. | International journal of clinical pharmacology and therapeutics 20080301 |
| Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. | Drugs in R&D 20080101 |
| Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. | Biomedical chromatography : BMC 20071101 |
| Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. | Epilepsy research 20071001 |
| Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. | Analytica chimica acta 20070716 |
| Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. | Biopharmaceutics & drug disposition 20070701 |
| Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. | Epilepsia 20070301 |
| Eslicarbazepine acetate (BIA 2-093). | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20070101 |
| Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. | Epilepsy research 20061201 |
| Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. | Journal of clinical pharmacology 20050901 |
| Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). | Drugs in R&D 20050101 |
| Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations. | Drugs in R&D 20050101 |
| Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. | Epilepsia 20041201 |
| Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. | Journal of clinical pharmacology 20040801 |
| Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. | Drugs in R&D 20030101 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. | Neurochemistry international 20020401 |
| Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. | Pharmacology & toxicology 20020401 |
| Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. | Neurochemical research 20020201 |
| Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. | Biochemical pharmacology 20010515 |
| Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. | Epilepsy research 20010501 |
| Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. | Epilepsia 20010501 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.